Pfizer to buy Wyeth for $68 billion
PHILADELPHIA/NEW YORK (Reuters) - Pfizer will halve its dividend and raise $22 billion in debt to buy rival Wyeth for $68 billion in an acquisition aimed at softening the blow of losing its biggest product to generic competition.<div class="feedflare">
<img src="http://feeds2.feedburner.com/~f/reuters/businessNews?d=41" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=QCNH9N1u) <img src="http://feeds2.feedburner.com/~f/reuters/businessNews?i=62xH8aNl" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=62xH8aNl) <img src="http://feeds2.feedburner.com/~f/reuters/businessNews?i=p3MKzUgw" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=p3MKzUgw)
</div><img src="http://feeds2.feedburner.com/~r/reuters/businessNews/~4/6IK95a1KlTg" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/businessNews/~3/6IK95a1KlTg/idUSTRE50M1AQ20090126